Pfizer lays out COVID-19 vaccine commercial strategy for pandemic and beyond Anthem seeing massive spike in use of telemedicine for behavioral health Roche arthritis drug Actemra flunks COVID-19 study, but remdesivir combo data await Sorrento picks up color-changing COVID-19 saliva test built by Columbia University fertility clinic Moderna's rumored $50-plus price on COVID-19 vaccine draws ire as company touts new animal data Camera maker Kodak dives into drug manufacturing with $765M federal loan Virtual behavioral health could expand access to care for 53M Americans, report finds Biopharma roundup: Do-it-yourself vaccine raises questions; Sanofi's Dupixent 'resilience' COVID-19 Special Report: Lessons in using healthcare web searches ExeVir bags €23M to take llama-derived COVID-19 drug into clinic Sanofi touts Dupixent's pandemic 'resilience' as cost cuts add up Shingrix crashes for GlaxoSmithKline as vaccination slows amid COVID-19 Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals XPrize launches $5M COVID-19 testing competition backed by Amazon, Google, Anthem Featured Story By Beth Snyder Bulik With its trials and pricing set, Pfizer has pulled back the curtain on the long-range commercial strategy for its COVID-19 vaccine. During its earnings call Tuesday, execs laid out two phases, pandemic and seasonal, with some combination of the two likely to play out over the next several years. read more |
| |
---|
| Top Stories By Paige Minemyer Anthem is the latest health insurer to report strong financial performance as COVID-19 drives down care utilization, earning $2.28 billion in profit in the second quarter. read more By Angus Liu Yet another attempt at repurposing existing drugs for COVID-19 appears to have failed. Roche said its arthritis med Actemra didn't top placebo at improving clinical status among patients with severe COVID-19 pneumonia, but the company is still counting on a combination with Gilead's remdesivir. read more By Conor Hale The single-step test aims to provide an easy-to-read result in less than 30 minutes just about anywhere. read more By Arlene Weintraub If Moderna prices its COVID-19 vaccine between $50 and $60 per course, as one report is suggesting, that would put it well above the $19.50-per-dose price set by Pfizer and BioNTech last week. One federal lawmaker is already blasting Moderna for profiting off taxpayers' investment in the vaccine. read more By Kyle Blankenship With COVID-19 straining international relations over the supply of needed generic medicines, the U.S. has scrambled to pump up domestic production of those key drugs. Now, the government is making a big splash to bring a well-known brand into the drug space—and it's not who you would expect. read more By Heather Landi The role of technology in response to COVID-19 is a tipping point for virtual behavioral health services. Virtual tools could materially expand access to behavioral health treatment for more than 53 million people, according to Accenture. Here are three factors healthcare providers need to consider to build out virtual care services. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner A group of scientists responded to the pandemic by creating a do-it-yourself vaccine that at least 20 people have taken, according to a report. Meanwhile, more drugmakers have unveiled second-quarter, pandemic-time results: Amgen's Otezla and Sanofi's Dupixent are posting growth as GlaxoSmithKline's gangbusters Shingrix rollout stalls. read more By Tina Reed Officials at Boston-based Kyruus — a company that offers provider search, scheduling, and data management — says one of the windows into understanding how to respond to patient demand has been watching the queries patients make as they search for information on health system websites. read more By Nick Paul Taylor ExeVir Bio has raised €23 million ($27 million) to advance a llama-derived antibody against COVID-19. The financing, which attracted the support of Fund+ and UCB, follows research showing an approach similar to that used by Ablynx can yield single-domain antibodiesthat neutralize SARS-CoV-2. read more By Eric Sagonowsky As part of CEO Paul Hudson’s transformation plan for Sanofi, the drugmaker has set out to cut €2 billion in annual expenses by 2022. So far, it’s making quick progress as COVID-19 tests its global operations. read more By Angus Liu Shingrix has been GlaxoSmithKline’s star growth driver since its introduction in 2017—but not so much now. Thanks to the pandemic, sales of Shingrix plummeted by half in the second quarter compared with the first, dragging the British pharma's overall performance down with it. read more By Eric Sagonowsky As companies worldwide grapple with challenges from the COVID-19 pandemic, Amgen is getting a boost from its newly acquired immunology blockbuster Otezla. The pill has bested the company's expectations despite the pandemic as it's "proved to be a convenient option” for patients, an exec said. read more By Heather Landi XPrize has launched a Rapid COVID Testing competition that will award $5 million to teams that develop faster, cheaper and easier-to-use COVID-19 testing methods at scale. Major payers Anthem and Cambia Health Solutions are backing the initiative along with Amazon and Google. Find out why the organizations believe innovation is key to accelerating testing efforts. read more |